Swiss Banks Stock News

SWX:ROG
SWX:ROGPharmaceuticals

Roche Trial Win In Rare Kidney Disease And What It Means For Valuation

Roche Holding (SWX:ROG) reported that its Phase III MAJESTY study in primary membranous nephropathy met its primary endpoint with Gazyva/Gazyvaro. The result positions Gazyva/Gazyvaro as a potential first approved treatment for this rare kidney condition. The outcome may support future regulatory submissions and broaden the medicine's approved indications. For you as an investor, this sits at the heart of what Roche does: prescription medicines targeting areas with significant unmet medical...
SWX:ACLN
SWX:ACLNElectrical

How Accelleron’s Board Succession Overhaul Will Impact Accelleron Industries (SWX:ACLN) Investors

Accelleron Industries has announced a major reshaping of its Board of Directors, proposing Monika Krüsi as Chairwoman and adding Mieke Van de Capelle, while two current directors step down early as part of an accelerated succession plan ahead of the 28 April 2026 AGM. This governance renewal could recalibrate how the company sets priorities in areas such as nomination, compensation, and sustainability oversight, potentially influencing its long-term direction. We’ll now examine how this...
SWX:SGSN
SWX:SGSNProfessional Services

Assessing SGS (SWX:SGSN) Valuation After Full-Year 2025 Earnings And Modest Share Price Gain

SGS earnings event and why it matters for shareholders SGS (SWX:SGSN) recently reported full year 2025 results, with sales of CHF 6,945 million and net income of CHF 668 million. Earnings per share from continuing operations were reported at CHF 3.48 on a basic basis. See our latest analysis for SGS. The share price reacted positively to the 2025 earnings announcement, with a 1 day share price return of 2.28%. The 90 day share price return of 3.81% and 3 year total shareholder return of...
SWX:NOVN
SWX:NOVNPharmaceuticals

Novartis (SWX:NOVN) Valuation Check After Vanrafia Phase III ALIGN Results Spark Investor Interest

Why the Vanrafia trial is moving Novartis shares Novartis (SWX:NOVN) is back in focus after final Phase III ALIGN data showed its drug Vanrafia slowed kidney function decline in adults with IgA nephropathy, reinforcing earlier approvals and helping spark fresh investor interest. See our latest analysis for Novartis. The Vanrafia update lands on top of a strong run for Novartis, with a 30 day share price return of 8.25% and a 90 day share price return of 18.30%. This has contributed to a 1...
SWX:UBSG
SWX:UBSGCapital Markets

Assessing UBS Group (SWX:UBSG) Valuation After Recent Share Price Volatility

Recent performance and context for UBS Group shares UBS Group (SWX:UBSG) has drawn investor attention after a monthly return of about a 16% decline and a 3‑month gain of roughly 4%, set against a backdrop of mixed shorter-term price moves. See our latest analysis for UBS Group. At a share price of CHF32.10, UBS Group’s recent 1 month share price return of a 16% decline and 7 day share price return of a 5% decline contrast with a 1 year total shareholder return of 9.8% and 5 year total...
SWX:HOLN
SWX:HOLNBasic Materials

Holcim’s WISC Initiative Sparks Fresh Look At 11.5% Undervaluation Debate

Why Holcim’s WISC initiative is catching investor attention Holcim (SWX:HOLN) has launched its Women in Sustainable Construction initiative, focusing on upskilling, industry engagement, and mentorship in the UAE. Investors are assessing what this could mean for the company’s long term positioning. See our latest analysis for Holcim. Holcim’s WISC launch comes after a softer patch in the share price, with a 7 day share price return of an 8.84% decline and a year to date share price return of a...
SWX:COTN
SWX:COTNElectronic

Did Surging FY 2024 Profitability in X-ray and RF Just Shift Comet Holding's (SWX:COTN) Investment Narrative?

Comet Holding AG recently reported FY 2024 revenue growth of 12.05% and very large net income growth of 128.22%, reflecting strong demand for its X-ray and RF power solutions in semiconductor and inspection markets. This performance, combined with anticipation ahead of the 6 March 2026 earnings release and AI-driven semiconductor investment trends, is sharpening attention on how effectively Comet converts sector demand into earnings quality and cash generation. We’ll now examine how this...
SWX:ZUGER
SWX:ZUGERBanks

Assessing Zuger Kantonalbank (SWX:ZUGER) Valuation After Digital Pension Launch Earnings Update And Dividend Increase

Zuger Kantonalbank (SWX:ZUGER) has drawn fresh attention after launching the fully digital Vaudoise InvestPlus pension solution with Vaudoise, alongside reporting full year 2025 earnings and announcing an annual dividend of CHF 230 per share. See our latest analysis for Zuger Kantonalbank. The recent Vaudoise InvestPlus launch, together with full year 2025 results and a higher dividend, has coincided with firming momentum. This includes a 30 day share price return of 8.35% and a 1 year total...
SWX:NOVN
SWX:NOVNPharmaceuticals

Novartis Kidney Data And Actinium Deal Shape Long Term Growth Story

Novartis (SWX:NOVN) reported positive final Phase III ALIGN results for Vanrafia in IgA nephropathy, indicating meaningful benefits in kidney function. The company also signed a long term supply agreement with Niowave for Actinium 225 to support its radioligand therapy portfolio. For investors watching SWX:NOVN, these updates come against a backdrop of solid recent share performance. The stock closed at CHF125.14 and is up 4.3% over the past week, 7.8% over the past month, 15.3% year to...
SWX:SCHN
SWX:SCHNMachinery

Schindler Holding (SWX:SCHN) Margin Improvement Tests Premium Valuation Narratives

Schindler Holding (SWX:SCHN) has wrapped up FY 2025 with fourth quarter revenue of CHF 2.8b and basic EPS of CHF 2.44, alongside trailing twelve month revenue of CHF 10.9b and EPS of CHF 9.48 that sit against earnings growth of 12.9% over the past year. The company has seen quarterly revenue move from CHF 2.9b in Q4 2024 to CHF 2.8b in Q4 2025, while basic EPS shifted from CHF 1.81 to CHF 2.44 over the same period, setting up a story where investors will be weighing solid earnings progress...
SWX:NESN
SWX:NESNFood

Assessing Nestlé (SWX:NESN) Valuation As Baby Formula Recall Drives 24 Hour Production

Nestlé (SWX:NESN) is in focus after a global baby formula recall linked to the cereulide toxin pushed the company to run five European factories 24 hours a day to support supply and consumer confidence. See our latest analysis for Nestlé. The recent safety driven ramp up in baby formula output comes after a period where momentum has been fairly muted. The share price return is 4.1% year to date, but the three year total shareholder return has declined by 20.1%, pointing to a company still...
SWX:UBSG
SWX:UBSGCapital Markets

Is UBS Group (SWX:UBSG) Trading Legal Risks for Efficiency in Its India Expansion Strategy?

In recent days UBS Group has moved to reshape its operations, announcing plans to build out a new global capability centre in Hyderabad, India that is expected to hire close to 3,000 professionals, alongside workforce reductions in Switzerland linked to the Credit Suisse integration, while also facing a US$5.5 million arbitration payout to former client Kyle Blackmon. Together, this expansion of UBS’s technology and operations footprint in India and the legal setback in the Blackmon case...
SWX:LOGN
SWX:LOGNTech

How Logitech’s New Value Wireless Headset Launch At Logitech International (SWX:LOGN) Has Changed Its Investment Story

Earlier this month, Logitech International launched the Logitech G325 LIGHTSPEED Wireless Gaming Headset, a US$79.99 wireless device featuring LIGHTSPEED connectivity, 24-bit audio, and cross-platform support for PC, console, and mobile. By packaging higher-end wireless performance, software customization through G HUB, and AI-powered noise reduction into a lower-priced headset, Logitech is targeting value-conscious gamers who still want advanced features. We’ll now examine how this...